WO2025105408A1 - 改変型酵素 - Google Patents

改変型酵素 Download PDF

Info

Publication number
WO2025105408A1
WO2025105408A1 PCT/JP2024/040387 JP2024040387W WO2025105408A1 WO 2025105408 A1 WO2025105408 A1 WO 2025105408A1 JP 2024040387 W JP2024040387 W JP 2024040387W WO 2025105408 A1 WO2025105408 A1 WO 2025105408A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
residue
substitution
hbdh
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/JP2024/040387
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
篤 大野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amano Enzyme Inc
Original Assignee
Amano Enzyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amano Enzyme Inc filed Critical Amano Enzyme Inc
Priority to CN202480072179.3A priority Critical patent/CN122180765A/zh
Priority to JP2025557884A priority patent/JPWO2025105408A1/ja
Publication of WO2025105408A1 publication Critical patent/WO2025105408A1/ja
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase

Definitions

  • the present invention relates to modified enzymes.
  • D-3-hydroxybutyrate dehydrogenase (HBDH: EC 1.1.1.30) is an enzyme that belongs to the short-chain dehydrogenase/reductase (SDR) family and catalyzes the reversible oxidation of 3-hydroxybutyrate to acetoacetate using NAD + as a coenzyme. Hydroxybutyrate, together with acetoacetate and acetone, is called a ketone body.
  • HBDH is an industrially important enzyme used to measure ketone bodies.
  • HBDH has been isolated from a variety of microorganisms.
  • Patent Document 1 discloses HBDH derived from Rhodobacter sphaeroides
  • Non-Patent Document 1 discloses HBDH derived from Paracoccus denitrificans
  • Non-Patent Document 2 discloses HBDH derived from Ralstonia pickettii T1
  • Non-Patent Document 3 discloses HBDH derived from Mycobacterium phlei ATCC354
  • Non-Patent Document 4 discloses HBDH derived from Staphylococcus xylosus
  • Non-Patent Document 5 discloses HBDH derived from Pseudomonas fragilis
  • Non-Patent Document 6 discloses HBDH derived from Alcaligenes faecalis
  • Non-Patent Document 7 discloses HBDH derived from Acidovorax sp.
  • strain SA1-derived HBDH is disclosed
  • non-patent document 8 discloses
  • HBDH derived from microorganisms is unstable to heat, but Patent Documents 2 and 3 disclose that HBDH derived from Alcaligenes faecalis and HBDH derived from Pseudomonas species, respectively, are HBDH with excellent heat stability, stable even at 37°C.
  • the present invention aims to provide an HBDH whose enzyme activity after treatment at at least one predetermined temperature in a temperature range of 40°C or higher is improved compared to the enzyme activity of wild-type HBDH after treatment at the predetermined temperature.
  • the present inventors attempted to modify HBDH derived from Ralstonia pickettii to impart heat resistance so as to increase activity after heat treatment. However, despite creating many mutants, few mutants with such heat resistance could be obtained. Among them, it was found by chance that a few mutants had heat resistance such that the enzyme activity after treatment at least at any given temperature in the temperature range of 40°C or higher was higher than the enzyme activity of wild-type HBDH after treatment at the said given temperature. That is, the present invention provides the invention of the following aspect.
  • a modified enzyme comprising a polypeptide shown in any one of (I) to (III) below:
  • (I) In the amino acid sequence shown in SEQ ID NO: 1, [A] substitution of the amino acid residue at position 47 with a methionine residue; [B] substitution of the amino acid residue at position 48 with a histidine residue; [C] substitution of the amino acid residue at position 49 with a leucine residue; [D] substitution of the amino acid residue at position 53 with a phenylalanine residue, a leucine residue, a proline residue, or a glutamic acid residue; [E] substitution of the amino acid residue at position 54 with a leucine residue, an alanine residue, or a phenylalanine residue; [F] substitution of the amino acid residue at position 55 with a glycine residue, a glutamic acid residue, a methionine residue, or a phenylalanine residue; [G] substitution of the amino acid residue at position 63 with a leucine residue
  • Item 2. A DNA encoding the modified enzyme according to Item 1.
  • Item 3. An expression cassette or a recombinant vector comprising the DNA according to Item 2.
  • Item 4. A transformant obtained by transforming a host with the expression cassette or recombinant vector according to Item 3.
  • Item 5. A method for producing a modified enzyme, comprising the step of culturing the transformant according to Item 4.
  • Item 6. An enzyme preparation comprising the modified enzyme according to Item 1.
  • Item 7. A sensor for measuring ketone bodies, comprising the modified enzyme according to Item 1.
  • Item 8. A kit for measuring ketone bodies, comprising the modified enzyme according to Item 1.
  • Item 9. A method for measuring ketone bodies in a sample, comprising the step of contacting the sample in which ketone bodies are to be measured with the modified enzyme under conditions for the activity of the modified enzyme according to Item 1.
  • the present invention provides a modified HBDH that has an improved enzyme activity after treatment at at least one of the predetermined temperatures in the temperature range of 40°C or higher, compared to the enzyme activity of wild-type HBDH after treatment at the predetermined temperature.
  • glycine (Gly) is G
  • alanine (Ala) is A
  • valine (Val) is V
  • leucine (Leu) is L
  • isoleucine (Ile) is I
  • phenylalanine (Phe) is F
  • tyrosine (Tyr) is Y
  • tryptophan (Trp) is W
  • serine (Ser) is S
  • threonine (Thr) is T
  • cysteine (Cys) is C
  • methionine (Met) is M
  • aspartic acid (Asp) is D
  • glutamic acid (Glu) is E
  • asparagine (Asn) is N
  • glutamine (Gln) is Q
  • lysine (Lys) is K
  • arginine (Arg) is R
  • histidine (His) is H
  • proline (Pro) is P.
  • nonpolar amino acids include alanine, valine, leucine, isoleucine, proline, methionine, phenylalanine, and tryptophan.
  • Uncharged amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
  • Acidic amino acids include aspartic acid and glutamic acid.
  • Basic amino acids include lysine, arginine, and histidine.
  • substitution includes not only cases where amino acid residue substitutions are artificially introduced, but also cases where amino acid residue substitutions are naturally introduced, i.e., cases where the amino acid residues are originally different.
  • amino acid residue substitutions may be either artificial or natural, with artificial substitutions being preferred.
  • Modified 3-hydroxybutyrate dehydrogenase (modified HBDH)
  • the modified enzyme of the present invention that is, the modified 3-hydroxybutyrate dehydrogenase, comprises a polypeptide shown in any one of (I) to (III) below.
  • amino acid sequence shown in SEQ ID NO:1 is the amino acid sequence of wild-type 3-hydroxybutyrate dehydrogenase (HBDH) derived from Ralstonia pickettii.
  • HBDH 3-hydroxybutyrate dehydrogenase
  • polypeptides (I) to (III) may be polypeptides containing any one of the above substitutions [A] to [O] alone (single substitution product of Ralstonia picketii-derived HBDH), or may be polypeptides containing two or more of them in combination (multiple substitution product of Ralstonia picketii-derived HBDH).
  • polypeptides (I) to (III) preferred examples include polypeptides containing at least one of the substitutions [A] to [O] shown in the "Type of substitution” column of Table 1.
  • each preferred substitution may be represented by the amino acid residue position and the amino acid residue after substitution, as shown in the "Abbreviation of substitution” column.
  • Specific sequences of the polypeptide (I) having each preferred substitution are shown in the "Sequence of the polypeptide (I)" column of Table 1.
  • the amino acid modification introduced may include only one type of modification (e.g., only substitution) from among substitution, addition, insertion, and deletion, or may include two or more types of modifications (e.g., substitution and insertion).
  • the number of amino acid differences in the portion other than the amino acid residue into which at least one of the substitutions shown in [A] to [O] has been introduced may be one or several, for example, 1 to 77, 1 to 60, 1 to 50, 1 to 40, or 1 to 30, preferably 1 to 25, 1 to 20, 1 to 15, more preferably 1 to 10, even more preferably 1 to 8, 1 to 7, 1 to 6, 1 to 5, or 1 to 4, even more preferably 1 to 3, and particularly preferably 1, 2, or 1.
  • sequence identity of the amino acids in the portion other than the amino acid residues into which at least one of the substitutions shown in [A] to [O] has been introduced may be 70% or more with respect to the corresponding portion of the amino acid sequence shown in SEQ ID NO:1, but is preferably 80% or more, more preferably 85% or more, even more preferably 90% or more, even more preferably 95% or more, 96% or more, 97% or more, 98% or more, and particularly preferably 99% or more or 99.5% or more.
  • sequence identity refers to the value of amino acid sequence identity obtained by the bl2seq program (Tatiana A. Tatsusova, Thomas L. Madden, FEMS Microbiol. Lett., Vol. 174, p247-250, 1999) of BLASTPACKAGE [sgi32 bit edition, Version 2.0.12; available from the National Center for Biotechnology Information (NCBI)].
  • NCBI National Center for Biotechnology Information
  • the amino acids at positions 16 (I), 154 (Y), 158 (K), 184 (P), 187 (V), and 189 (T) in the amino acid sequence shown in SEQ ID NO: 1 are thought to contribute to the binding of NAD (nicotinamide adenine dinucleotide), and the amino acids at positions 93 (Q), 141 (S), 143 (H), 151 (K), and 154 (Y) are thought to contribute to the binding of the substrate, and all of these are thought to contribute to 3-hydroxybutyrate dehydrogenase activity, so it is preferable not to introduce substitutions or deletions at these positions.
  • conservative substitutions in the polypeptides (II) and (III) include, for example, substitution with another nonpolar amino acid if the amino acid before substitution is a nonpolar amino acid, substitution with another uncharged amino acid if the amino acid before substitution is an uncharged amino acid, substitution with another acidic amino acid if the amino acid before substitution is an acidic amino acid, and substitution with another basic amino acid if the amino acid before substitution is a basic amino acid.
  • the heat resistance of the polypeptides (II) and (III) is "improved over that of the polypeptide having the amino acid sequence shown in SEQ ID NO: 1" means that the HBDH activity after treatment at at least one of the predetermined temperatures in the temperature range of 40°C or higher is higher than the HBDH activity of the polypeptide having the amino acid sequence shown in SEQ ID NO: 1 after treatment at the predetermined temperature.
  • the improved heat resistance of the polypeptides (II) and (III) may be observed at at least one of the predetermined temperatures in the temperature range of 40°C or higher (the time for exposure to the predetermined temperature is 15 minutes), and the temperature range is preferably 45°C or higher.
  • the heat resistance of the polypeptide having the amino acid sequence shown in SEQ ID NO: 1 is significantly deteriorated at 50°C or higher, and therefore the temperature range is more preferably 50°C or higher.
  • the upper limit of the temperature range is not particularly limited, but may be, for example, 60°C or lower, preferably 55°C or lower. Specific examples of the temperature range include 40 to 60°C, 45 to 60°C, 50 to 60°C, or 50 to 55°C.
  • DNA of the present invention is a DNA encoding the above-mentioned "1. Modified 3-hydroxybutyrate dehydrogenase (modified HBDH)”.
  • the DNA of the present invention is not particularly limited as long as it has a base sequence that encodes a modified HBDH consisting of the polypeptides shown in (I) to (III) described in "1. Modified 3-hydroxybutyrate dehydrogenase (modified HBDH)" above.
  • Examples of the DNA of the present invention include DNAs shown in any of (i) to (iii) below.
  • DNA in (i) above can be easily determined by a person skilled in the art based on the base sequence of SEQ ID NO: 13.
  • DNA encoding the polypeptides shown in SEQ ID NOs: 2 to 12 in Table 1 include the base sequences of SEQ ID NOs: 14 to 24, respectively.
  • under stringent conditions refers to conditions in which the DNA is incubated at 50°C to 65°C for 4 hours to overnight in 6xSSC (1xSSC is 0.15M NaCl, 0.015M sodium citrate, pH 7.0) containing 0.5% SDS, 5x Denhartz's (0.1% bovine serum albumin (BSA), 0.1% polyvinylpyrrolidone, 0.1% Ficoll 400) and 100 ⁇ g/ml salmon sperm DNA.
  • 6xSSC 0.15M NaCl, 0.015M sodium citrate, pH 7.0
  • hybridization under stringent conditions is carried out by the following method. That is, a nylon membrane on which a DNA library or a cDNA library is immobilized is prepared, and the nylon membrane is blocked at 65° C. in a prehybridization solution containing 6 ⁇ SSC, 0.5% SDS, 5 ⁇ Denhardt's, and 100 ⁇ g/ml salmon sperm DNA. Then, each probe labeled with 32 P is added and incubated overnight at 65° C. The nylon membrane is washed in 6 ⁇ SSC at room temperature for 10 minutes, in 2 ⁇ SSC containing 0.1% SDS at room temperature for 10 minutes, and in 0.2 ⁇ SSC containing 0.1% SDS at 45° C. for 30 minutes, and then autoradiography is performed to detect DNA that has specifically hybridized with the probe.
  • the homology may be 70% or more, but is preferably 80% or more or 85% or more, more preferably 90% or more or 93% or more, even more preferably 95% or more, even more preferably 98% or more, even more preferably 98.5% or more or 99% or more, and particularly preferably 99.3% or more or 99.5% or more.
  • DNA "homology” is calculated using publicly available or commercially available software with an algorithm for comparing a reference sequence with a query sequence. Specifically, BLAST, FASTA, or GENETYX (manufactured by Genetyx Corporation) can be used, and these can be used with the default parameters.
  • the DNA of the present invention can be obtained, for example, by introducing at least one of the substitutions [a] to [o] above into DNA encoding a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:1 (wild-type HBDH derived from Ralstonia picketii).
  • the DNA of the present invention can also be artificially synthesized by total gene synthesis.
  • the base sequence portion can be obtained by standard methods using PCR from a nucleic acid construct such as a plasmid incorporating the base sequence shown in SEQ ID NO:13.
  • Methods for introducing a mutation into a gene and artificially modifying the amino acid sequence include known techniques such as the Kunkel method and the Gapped duplex method, and mutation introduction kits using site-specific mutagenesis, such as QuikChange TM Site-Directed Mutagenesis Kit (Stratagene), GeneTailor TM Site-Directed Mutagenesis System (Invitrogen), and TaKaRa Site-Directed Mutagenesis System (Mutan-K, Mutan-Super Express Km, etc.: Takara Bio Inc.).
  • the DNA of the present invention includes various types of DNA resulting from codon degeneracy.
  • Various types of DNA encoding the same amino acid sequence can be artificially produced easily using known genetic engineering techniques. For example, in the genetic engineering production of a protein, if the codons used in the original gene encoding the target protein are used infrequently in the host, the expression level of the protein may be low. In such cases, the codon usage frequency can be optimized for the host without changing the encoded amino acid sequence, thereby achieving high expression of the target protein.
  • the sum of the host optimal codon usage frequencies for each codon can be used as an index of codon usage frequency.
  • An optimal codon is defined as the codon with the highest usage frequency among the codons corresponding to the same amino acid. There are no particular limitations on the codon usage frequency as long as it is optimized for the host, but the following is an example of an optimal codon for E.
  • coli F: phenylalanine (ttt), L: leucine (ctg), I: isoleucine (att), M: methionine (atg), V: valine (gtg), Y: tyrosine (tat), stop codon (taa), H: histidine (cat), Q: glutamine (cag), N: asparagine (aat), K: lysine (aaa), D: aspartic acid (gat), E: glutamic acid (gaa), S: serine (agc), P: proline (ccg), T: threonine (acc), A: alanine (gcg), C: cysteine (tgc), W: tryptophan (tgg), R: arginine (cgc), G: glycine (ggc).
  • the base sequence of DNA into which a mutation has been introduced can be confirmed by conventional sequencing methods.
  • Specific sequencing methods include the dideoxynucleotide chain termination method (Sanger et al. (1977) Proc. Natl. Acad. Sci. USA 74:5463) or sequence analysis using an appropriate DNA sequencer.
  • Methods for confirming whether or not the DNA encodes a target polypeptide include a method of comparing the determined base sequence with an unsubstituted base sequence such as the base sequence shown in SEQ ID NO:13, or a method of comparing the amino acid sequence deduced from the determined base sequence with an unsubstituted amino acid sequence such as the amino acid sequence shown in SEQ ID NO:1.
  • the expression cassette or recombinant vector of the present invention contains the DNA of the present invention described above in "2. DNA.”
  • the expression cassette or recombinant vector of the present invention can be obtained by linking a promoter and a terminator to the DNA of the present invention, or by inserting the expression cassette of the present invention or the DNA of the present invention into an expression vector.
  • the expression cassette or recombinant vector of the present invention may contain, as control elements, a promoter and a terminator, as well as transcription elements such as an enhancer, a CCAAT box, a TATA box, and an SPI site, if necessary. These control elements may be operably linked to the DNA of the present invention. "Operably linked" means that the various control elements that regulate the DNA of the present invention are linked to the DNA of the present invention in a state that allows them to operate in a host cell.
  • an expression vector constructed for genetic recombination from a phage, plasmid, or virus capable of autonomously replicating in a host is suitable.
  • Such expression vectors are known, and examples of commercially available expression vectors include pQE-series vectors (Qiagen, Inc.), pTrc99A, pDR540, pRIT2T (GE Healthcare Biosciences, Inc.), and pET-series vectors (Merck, Inc.).
  • the expression vector may be used in an appropriate combination with the host cell, and examples of such combinations include, when E. coli is used as the host cell, a combination of a pET-series vector and a DH5 ⁇ E. coli strain, a combination of a pET-series vector and a BL21 (DE3) E. coli strain, or a combination of a pDR540 vector and a JM109 E. coli strain.
  • Transformant of the present invention is obtained by transforming a host with the expression cassette or recombinant vector of the present invention described above in "3. Expression cassette or recombinant vector.”
  • the host used to produce the transformant of the present invention is not particularly limited as long as it allows the introduction of a gene, the expression cassette or recombinant vector is stable, and is capable of autonomous replication and capable of expressing the traits of the gene containing the DNA of the present invention.
  • Suitable examples include bacteria belonging to the genus Escherichia such as Escherichia coli, the genus Bacillus such as Bacillus subtilis, the genus Pseudomonas such as Pseudomonas putida, and the genus Chryseobacterium such as Chryseobacterium proteolyticum; yeast, etc., but other examples include animal cells, insect cells, and plant cells.
  • the transformant of the present invention can be obtained by introducing the expression cassette of the present invention or the recombinant vector of the present invention into a host.
  • the location of the DNA of the present invention to be introduced is not particularly limited as long as the gene of interest can be expressed, and may be on a plasmid or on a genome.
  • Specific methods for introducing the expression cassette of the present invention or the recombinant vector of the present invention include, for example, a recombinant vector method and a genome editing method.
  • Conditions for introducing the expression cassette or recombinant vector into a host may be appropriately set according to the type of host, etc.
  • the host is a bacterium, for example, a method using competent cells treated with calcium ions and an electroporation method are included.
  • an electroporation method electroporation method
  • a spheroplast method a lithium acetate method
  • an animal cell for example, an electroporation method, a calcium phosphate method, and a lipofection method are included.
  • an insect cell for example, a calcium phosphate method, a lipofection method, and an electroporation method are included.
  • an electroporation method, an Agrobacterium method, a particle gun method, and a PEG method are included.
  • genomic DNA, the expression cassette, or the recombinant vector may be isolated and purified from the transformant.
  • the expression cassette or recombinant vector is isolated and purified based on the lysate obtained by lysing the bacteria.
  • the lysis method involves treatment with a lytic enzyme such as lysozyme, and if necessary, the use of a protease, other enzymes, and a surfactant such as sodium lauryl sulfate (SDS) is also used.
  • a lytic enzyme such as lysozyme
  • SDS sodium lauryl sulfate
  • DNA can be separated and purified from the lysate by, for example, an appropriate combination of deproteinization treatment using phenol treatment and protease treatment, ribonuclease treatment, alcohol precipitation treatment, and commercially available kits.
  • DNA can be cut in the usual way, for example by using a restriction enzyme treatment.
  • a type II restriction enzyme that acts on a specific nucleotide sequence is used as the restriction enzyme.
  • DNA is linked to an expression cassette or expression vector, for example by using DNA ligase.
  • primers specific to the DNA of the present invention are designed and PCR is performed.
  • the amplified products obtained by PCR are subjected to agarose gel electrophoresis, polyacrylamide gel electrophoresis, capillary electrophoresis, etc., and stained with ethidium bromide and SYBR Green solution, etc., and the amplified products are detected as bands, thereby confirming that transformation has occurred.
  • the method for producing the modified 3-hydroxybutyrate dehydrogenase of the present invention is a method for producing the enzyme described in "1. Modified 3-hydroxybutyrate dehydrogenase (modified HBDH)" above, and includes a step of culturing the transformant of the present invention.
  • the modified HBDH can be obtained by a production method including a step of culturing a microorganism that produces the modified HBDH.
  • the above culture conditions may be appropriately set in consideration of the nutritional and physiological properties of the transformant or the microorganism, and liquid culture is preferred. In the case of industrial production, aeration and stirring culture is preferred.
  • the nutrient source for the medium any nutrient required for the growth of the transformant or the microorganism may be used.
  • the carbon source any assimilable carbon compound may be used, such as glucose, sucrose, lactose, maltose, molasses, pyruvic acid, etc.
  • any assimilable nitrogen compound may be used, such as peptone, meat extract, yeast extract, casein hydrolysate, and soybean meal alkaline extract.
  • salts such as phosphates, carbonates, sulfates, magnesium, calcium, potassium, iron, manganese, and zinc, specific amino acids, and specific vitamins may be used as necessary.
  • the culture temperature can be set appropriately within a range in which the transformant or microorganism of the present invention can grow and the transformant or microorganism can produce modified HBDH, but is preferably about 15 to 45°C, and more preferably about 25 to 39°C.
  • the culture may be completed at an appropriate time when the modified HBDH reaches its maximum yield, and the culture time is usually about 12 to 48 hours.
  • the culture solution can be subjected to a separation method such as centrifugation to recover the culture supernatant and/or the bacterial cells.
  • the bacterial cells can be treated with mechanical methods such as ultrasonication or French press, or with a lytic enzyme such as lysozyme, and if necessary, solubilized using an enzyme such as protease or a surfactant such as sodium lauryl sulfate (SDS), to obtain a water-soluble fraction containing the desired modified HBDH.
  • SDS sodium lauryl sulfate
  • the expressed modified HBDH can be secreted into the culture solution.
  • the water-soluble fraction containing the modified HBDH obtained as described above may be subjected to a purification treatment as it is, or the modified HBDH in the water-soluble fraction may be concentrated and then subjected to a purification treatment.
  • concentration may be performed, for example, by vacuum concentration, membrane concentration, salting out treatment, or fractional precipitation using a hydrophilic organic solvent (e.g., methanol, ethanol, and/or acetone).
  • a hydrophilic organic solvent e.g., methanol, ethanol, and/or acetone
  • the purification process of the modified HBDH can be carried out by appropriately combining methods such as gel filtration, adsorption chromatography, ion exchange chromatography, and affinity chromatography.
  • the purified modified HBDH may be powdered by freeze drying, vacuum drying, spray drying, etc., if necessary.
  • the modified HBDH can be provided in the form of an enzyme preparation.
  • the present invention also provides an enzyme preparation comprising the modified HBDH described in "1. Modified 3-hydroxybutyrate dehydrogenase (modified HBDH)" above as an active ingredient.
  • modified HBDH in the enzyme preparation of the present invention is not particularly limited as long as the activity of the active ingredient modified HBDH is exhibited when the enzyme preparation is used.
  • the enzyme preparation of the present invention may or may not contain other components in addition to the modified HBDH, to the extent that the effects of the present invention can be obtained.
  • other components include enzymes other than the modified HBDH, additives, culture residues generated in the above-mentioned production method, etc.
  • enzymes include, for example, amylase ( ⁇ -amylase, ⁇ -amylase, glucoamylase), glucosidase ( ⁇ -glucosidase, ⁇ -glucosidase), galactosidase ( ⁇ -galactosidase, ⁇ -galactosidase), protease (acid protease, neutral protease, alkaline protease), peptidase (leucine peptidase, aminopeptidase), lipase, esterase, cellulase, phosphatase (acid phosphatase, alkaline phosphatase), nuclease, deaminase, oxidase, dehydrogenase (other than the above modified HBDH), glutaminase, pectinase, catalase, dextranase, transglutaminase, protein deamidating enzyme, pullulanase,
  • Additives include excipients, buffers, suspending agents, stabilizers, preservatives, antiseptics, and physiological saline.
  • Excipients include starch, dextrin, maltose, trehalose, lactose, D-glucose, sorbitol, D-mannitol, sucrose, and glycerol.
  • Buffers include phosphates, citrates, and acetates.
  • Stabilizers include propylene glycol and ascorbic acid.
  • Preservatives include phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, and methylparaben.
  • Preservatives include ethanol, benzalkonium chloride, paraoxybenzoic acid, and chlorobutanol. These additives may be contained alone or in combination.
  • Culture residues include components derived from the culture medium, contaminating proteins, bacterial components, etc.
  • the form of the enzyme preparation of the present invention is not particularly limited, and examples include liquid and solid forms (powder, granules, etc.).
  • the enzyme preparation in the above form can be prepared by a generally known method.
  • the use of the enzyme preparation of the present invention is not particularly limited as long as it is an application that generally utilizes the activity of HBDH.
  • a preferred application is the measurement of ketone bodies.
  • the ketone body to be measured is 3-hydroxybutyric acid (R-3-hydroxybutyric acid). Ketone body measurement will be described in detail in "9. Method for measuring ketone bodies in a sample.”
  • the modified HBDH can be used as a sensing means in a sensor for measuring ketone bodies.
  • the present invention also provides a sensor for measuring ketone bodies, comprising the modified HBDH described in "1. Modified 3-hydroxybutyrate dehydrogenase (modified HBDH)" above.
  • the ketone body measuring sensor of the present invention can be configured as an entity that contains the above-mentioned modified HBDH and converts the change and the amount of change based on the reaction of the modified HBDH with 3-hydroxybutyric acid (R-3-hydroxybutyric acid) and NAD + (nicotinamide adenine dinucleotide) and/or its derivatives into a readable signal.
  • 3-hydroxybutyric acid R-3-hydroxybutyric acid
  • NAD + nicotinamide adenine dinucleotide
  • Signals that can read the change and its amount based on the reaction of 3-hydroxybutyric acid (R-3-hydroxybutyric acid) with NAD + and/or its derivatives by the above-mentioned modified HBDH include electrochemical signals and optical signals.
  • Electrochemical signals include those in which a chemical state (e.g., the presence of 3-hydroxybutyrate) is converted into an electrical signal (e.g., an electric current).
  • Optical signals include light absorption and/or emission based on the redox state of NAD + and/or its derivatives (e.g., the presence of NAD + and/or its derivatives, and/or NADH and/or its derivatives).
  • the modified HBDH is preferably immobilized on an insoluble support.
  • the manner of immobilization of the modified HBDH is not particularly limited, and examples include physical immobilization by adhesion, adsorption, absorption, swelling, etc., chemical or biochemical immobilization by specific non-covalent bonds, and chemical immobilization by covalent bonds.
  • the modified HBDH may be immobilized on an insoluble support by itself, or may be immobilized on an insoluble support together with other components in the form of a composition.
  • a specific embodiment in which the modified HBDH is immobilized on an insoluble support in the form of a composition is one in which the composition is physically immobilized (preferably by adhesion) on the insoluble support.
  • At least the surface of the insoluble support is composed of a solid or solid material that does not dissolve in the reaction system between the modified HBDH and 3-hydroxybutyric acid and can immobilize the modified HBDH.
  • materials that compose at least the surface of the insoluble support include swellable materials (e.g., gelatin, etc.), porous substrates (e.g., cellulose, filter paper, etc.), resins, glass, redox polymers (i.e., polymers to which a redox mediator is bound), metals, carbon, etc.
  • the shape of the insoluble carrier is not particularly limited, and examples include substrates, flakes, sticks, beads, etc.
  • modified HBDH is preferably physically fixed to such an electrode, and more preferably, a composition containing modified HBDH is physically fixed (preferably by attachment).
  • ketone body measurement sensor of the present invention may be any form used as a biosensor, such as a sensor chip, a microtiter plate, a test strip, an electrochemical flow cell, etc.
  • Ketone body measurement kit The ketone body measurement kit of the present invention includes an enzyme preparation described in "6. Enzyme preparation” above that is used for ketone body measurement (hereinafter also referred to as “enzyme preparation for ketone body measurement”) or a ketone body measurement sensor described in “7. Sensor for ketone body measurement” above.
  • the ketone body measurement kit of the present invention may further include other suitable items used for measurement and/or sample collection in addition to the ketone body measurement enzyme preparation or ketone body measurement sensor.
  • ketone body measurement kit of the present invention may contain one of these other items alone or a combination of multiple items.
  • coenzymes examples include NAD + (nicotinamide adenine dinucleotide), NAD + derivatives (e.g., nicotinamide adenine dinucleotide phosphate (NADP + ), thionicotinamide-NAD, pyridine aldehyde-NAD, acetylpyridine-NAD, carba-NAD, etc.), FAD + (flavin adenine dinucleotide), etc.
  • NAD + and NADP + are preferable.
  • reducing reagents include Nitrotetrazolium Blue and Tetrazolium Blue. These reducing reagents may be used alone or in combination.
  • redox mediators examples include 1-methoxy-5-methylphenazinium methylsulfur, 1-methoxy-phenazine methosulfate, 1-methoxy-phenazinium ethylsulfate, thiol-reactive PES, and amine-reactive PES. These redox mediators may be used alone or in combination. Of these redox mediators, 1-methoxy-5-methylphenazinium methylsulfur is preferred.
  • buffer solution examples include acetate buffer, phosphate buffer, triethanolamine buffer, Tris-HCl buffer, and GOOD's buffer.
  • GOOD's buffer solutions include PIPES, MES, and MOPS. These buffer solutions may be used alone or in combination. Among these buffer solutions, GOOD's buffer solution is preferred, and PIPES is more preferred.
  • the method for measuring ketone bodies in a sample of the present invention comprises the step of contacting a sample in which ketone bodies are to be measured with the modified HBDH described above in "1. Modified 3-hydroxybutyrate dehydrogenase (HBDH)" under 3-hydroxybutyrate dehydrogenase activity conditions.
  • HBDH Modified 3-hydroxybutyrate dehydrogenase
  • the method of the present invention for measuring ketone bodies in a sample is based on the following reaction catalyzed by modified HBDH.
  • the method of the present invention for measuring ketone bodies in a sample includes the steps of: (a) contacting a sample containing 3-hydroxybutyric acid with the modified HBDH; (b) reacting 3-hydroxybutyric acid in the sample with NAD + (nicotinamide adenine dinucleotide) and/or a derivative thereof by the modified HBDH; and (c) detecting or quantifying a change based on the reaction between 3-hydroxybutyric acid (R-3-hydroxybutyric acid) and NAD + and/or a derivative thereof.
  • the method may further include a step of inactivating the modified HBDH after step (b) and before step (c).
  • the sample is not particularly limited as long as it is a sample in which ketone bodies are to be measured, and examples include biological samples derived from a subject in which ketone bodies are to be measured.
  • Subjects in which ketone bodies are to be measured include mammals such as humans.
  • Biological samples include body fluids, excrement, and tissues, and specific examples include blood samples (whole blood, serum, plasma), urine, semen, prostatic fluid, tears, saliva, sweat, ascites, cerebrospinal fluid, milk, lymph, tissue extract samples, etc.
  • the modified HBDH can be used in an amount of, for example, 0.1 ⁇ g or more, preferably 1.0 ⁇ g or more, more preferably 5.0 ⁇ g or more, even more preferably 10 ⁇ g or more, and particularly preferably 15 ⁇ g or more per gram of 3-hydroxybutyric acid in the sample.
  • the upper limit of the amount used is not particularly limited, but examples include amounts of, for example, 10,000 ⁇ g or less, preferably 1,000 ⁇ g or less, more preferably 500 ⁇ g or less, even more preferably 100 ⁇ g or less, and particularly preferably 50 ⁇ g or less per gram of 3-hydroxybutyric acid in the sample. These amounts can be determined through preliminary experiments.
  • a coexistence system of the sample and the modified HBDH may be constructed.
  • (a1) a mixed solution of the sample and an enzyme agent described in "6. Enzymes" above that is used for measuring ketone bodies (enzyme agent for measuring ketone bodies) may be prepared, or (a2) a coexistence system of the sample and the modified HBDH may be constructed by dropping, placing, pouring, absorbing, etc. the sample onto an insoluble support on which an active ingredient (modified HBDH) is fixed in the ketone body measurement sensor described in "7. Sensor for measuring ketone bodies” above, or by immersing the insoluble support in the sample.
  • the coexistence system of the sample and modified HBDH may further contain the coenzymes, reducing reagents, redox mediators, and/or buffer solutions described above in "8. Ketone body measurement kits.”
  • the amount of the coenzymes used per 1 g of modified HBDH may be, for example, 0.01 to 100 mol, preferably 0.1 to 10 mol, more preferably 0.1 to 10 mol, even more preferably 0.5 to 5.0 mol, and even more preferably 0.8 to 3.0 mol.
  • the amount of the reducing reagent used per 1 g of modified HBDH may be, for example, 0.01 to 100 mol, preferably 0.1 to 50 mol, more preferably 0.1 to 10 mol, even more preferably 0.5 to 5.0 mol, and even more preferably 0.8 to 3.0 mol.
  • the amount of the redox mediator used per 1 g of modified HBDH is, for example, 0.01 to 100 mol, preferably 0.1 to 50 mol, more preferably 0.1 to 10 mol, even more preferably 0.5 to 5.0 mol, and even more preferably 0.8 to 3.0 mol.
  • the reaction conditions are appropriately selected by those skilled in the art as temperature and pH conditions that cause the 3-hydroxybutyrate dehydrogenase activity of the modified HBDH.
  • the reaction temperature is specifically, for example, 5 to 80°C, preferably 10 to 70°C, more preferably 15 to 60°C, even more preferably 20 to 55°C, even more preferably 25 to 50°C, and even more preferably 30 to 50°C.
  • the reaction pH can be based on the optimal pH of the modified HBDH, specifically, 3 to 9, preferably 5 to 8, and more preferably 6 to 7.5.
  • the reaction time is not particularly limited, but is, for example, 10 seconds to 12 hours, preferably 30 seconds to 1 hour, and more preferably 1 minute to 30 minutes. The optimal conditions for these reaction conditions can be determined through preliminary experiments.
  • steps (a) and (b) may be performed in this order, or may be performed simultaneously.
  • the NAD + derivative is not particularly limited as long as it has NAD + as a base skeleton and, like NAD + , produces a reduced form when 3-hydroxybutyrate is converted to acetoacetate by the modified HBDH.
  • the NAD+ derivative include nicotinamide adenine dinucleotide phosphate, thionicotinamide-NAD, pyridine aldehyde-NAD, acetylpyridine-NAD, carba-NAD, and the like.
  • the change due to the reaction between 3-hydroxybutyric acid and NAD + and/or its derivatives is as described above in "7. Sensor for measuring ketone bodies.”
  • the change due to the reaction between 3-hydroxybutyric acid and NAD + and/or its derivatives correlates with the amount of 3-hydroxybutyric acid contained in the sample. Therefore, by detecting or quantifying the change due to the reaction, the 3-hydroxybutyric acid contained in the sample can be detected or quantified.
  • the amount of NADH and/or its derivatives produced, the amount of NAD + and/or its derivatives consumed, and/or the ratio of these amounts can be measured as the amount of change due to the above reaction, based on the fact that the amount of NADH and/or its derivatives produced and the amount of NAD + and/or its derivatives consumed are correlated with the amount of 3-hydroxybutyric acid present in the sample.
  • the method of calculating these amounts and ratios can be appropriately determined by one skilled in the art.
  • Genomic DNA was extracted from Ralstonia pickettii. Using the gene sequence (SEQ ID NO: 13) of 3-hydroxybutyrate dehydrogenase (HBDH) as a template, saturation mutagenesis was performed to obtain a group of mutant gene products. Each of the obtained mutant gene products was introduced into pTrc99A, and E. coli JM109 was transformed by a conventional method. The obtained transformants were cultured with shaking at 37°C for 16 hours in LB-Lennox medium (1% Bacto Trypton: Thermo Fisher Scientific, 0.5% Bacto Yeast Extract: Thermo Fisher Scientific, 0.5% sodium chloride: Fuji Film Wako).
  • the cells were subcultured in Terrific Broth (1.2% Bacto Trypton: Thermo Fisher Scientific, 2.4% Bacto Yeast Extract: Thermo Fisher Scientific, 0.8% glycerol: Fuji Film Wako, 0.94% dipotassium hydrogen phosphate: Fuji Film Wako, 0.22% dipotassium hydrogen phosphate: Fuji Film Wako) and cultured with shaking at 37 ° C. for 20 hours.
  • the cells were collected from the culture medium, disrupted using a bead shocker (Yasui Kikai) in the usual manner, and centrifuged at 15,000 rpm for 10 minutes. The collected centrifugal supernatant was used as a crude enzyme solution.
  • the crude enzyme solution was treated at 40°C for 15 minutes, after which HBDH activity was measured and the residual activity was calculated. 1,500 mutant strains were evaluated, but only 11 strains were confirmed to have a heat-resistant effect compared to the wild type. Sequence analysis was performed on the strains that were confirmed to have a heat-resistant effect, and the substituted amino acids were confirmed. As a result, the amino acid sequences of SEQ ID NOs: 2 to 12 were identified.
  • the crude enzyme solution of the strains that were confirmed to have heat resistance was purified by standard methods such as adsorption chromatography and ultrafiltration to obtain purified enzyme samples of modified HBDH having the amino acid sequences of SEQ ID NOs: 2 to 12, respectively.
  • the protein concentration of the prepared purified enzyme samples was measured using Biorad Protein Assay Reagent (Biorad).
  • the purified enzyme samples were diluted with 50 mM phosphate buffer (pH 7.5) to 0.1 mg/ml to equalize the protein concentration. 100 ⁇ L of each was placed in a PCR tube (BM Equipment) and heated for 15 minutes at 40°C, 45°C, 50°C, 55°C, or 60°C in a thermal cycler (Applied Biosystems). The samples were then quickly cooled on ice, and the HBDH activity of the resulting sample solution was measured as follows.
  • Table 2a shows the relative HBDH activity (%) of each Example, when the HBDH activity after each temperature treatment in Comparative Example 1 is taken as 100%.
  • Table 2b shows the relative HBDH activity (%) after each temperature treatment, when the HBDH activity at 4°C is taken as 100%.
  • the protein concentration of the prepared purified enzyme samples was measured using Biorad Protein Assay Reagent (Biorad).
  • the purified enzyme samples were diluted with 50 mM phosphate buffer (pH 7.5) to 0.1 mg/ml to equalize the protein concentration. 100 ⁇ L of each was placed in a PCR tube (BM Equipment) and heated for 15 minutes at 40°C, 45°C, 50°C, 55°C, or 60°C in a thermal cycler (Applied Biosystems). The samples were then promptly cooled on ice, and the HBDH activity of the resulting sample solution was measured as follows.
  • a substrate solution was prepared consisting of 600 mmol/L 3-hydroxybutyric acid, 60 mmol/L ⁇ -NAD, 6.6 mmol/L 1-methoxy-5-methylphenazinium methylsulfur, 6.6 mmol/L nitrotetrazolium blue chloride, and 100 mmol/L PIPES-NaOH buffer (pH 7.0) containing 0.1 g/dL (final concentration) of Triton X-100. 10 ⁇ L of sample solution diluted to a specified ratio was added to 200 ⁇ L of substrate solution at 37°C, and the change in absorbance at 570 nm was measured.
  • Table 3a shows the relative HBDH activity (%) of each Example, when the HBDH activity after each temperature treatment in Comparative Example 1 is taken as 100%.
  • Table 3b shows the relative HBDH activity (%) after each temperature treatment, when the HBDH activity at 4°C is taken as 100%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
PCT/JP2024/040387 2023-11-15 2024-11-13 改変型酵素 Pending WO2025105408A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202480072179.3A CN122180765A (zh) 2023-11-15 2024-11-13 修饰型酶
JP2025557884A JPWO2025105408A1 (cg-RX-API-DMAC7.html) 2023-11-15 2024-11-13

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-194701 2023-11-15
JP2023194701 2023-11-15

Publications (1)

Publication Number Publication Date
WO2025105408A1 true WO2025105408A1 (ja) 2025-05-22

Family

ID=95742292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/040387 Pending WO2025105408A1 (ja) 2023-11-15 2024-11-13 改変型酵素

Country Status (3)

Country Link
JP (1) JPWO2025105408A1 (cg-RX-API-DMAC7.html)
CN (1) CN122180765A (cg-RX-API-DMAC7.html)
WO (1) WO2025105408A1 (cg-RX-API-DMAC7.html)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01318438A (ja) 1988-06-20 1989-12-22 Hitachi Ltd 移動電話端末方式
JPH0870856A (ja) 1994-09-01 1996-03-19 Asahi Chem Ind Co Ltd 3−ヒドロキシ酪酸脱水素酵素を生産する実質上純粋な微生物
JP2003339385A (ja) 2002-05-29 2003-12-02 Toyobo Co Ltd 新規3−ヒドロキシ酪酸脱水素酵素遺伝子、新規3−ヒドロキシ酪酸脱水素酵素の製造法、ならびに、新規3−ヒドロキシ酪酸脱水素酵素を用いたケトン体の測定方法および測定用組成物
JP2019505193A (ja) * 2015-12-21 2019-02-28 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft アルカリゲネス・フェーカリス由来の変異型3−ヒドロキシ酪酸デヒドロゲナーゼ並びにそれに関する方法および使用
JP2019511245A (ja) * 2016-02-09 2019-04-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ロドバクター・スフェロイデス(Rhodobacter sphaeroides)由来の変異型3−ヒドロキシブチレート脱水素酵素及びそれを含む方法
WO2021149675A1 (ja) * 2020-01-24 2021-07-29 東洋紡株式会社 3-ヒドロキシ酪酸脱水素酵素及びその製造方法
WO2021210614A1 (ja) * 2020-04-17 2021-10-21 天野エンザイム株式会社 ケトン体測定用酵素剤、ケトン体測定用センサ及び試料中のケトン体を測定する方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01318438A (ja) 1988-06-20 1989-12-22 Hitachi Ltd 移動電話端末方式
JPH0870856A (ja) 1994-09-01 1996-03-19 Asahi Chem Ind Co Ltd 3−ヒドロキシ酪酸脱水素酵素を生産する実質上純粋な微生物
JP2003339385A (ja) 2002-05-29 2003-12-02 Toyobo Co Ltd 新規3−ヒドロキシ酪酸脱水素酵素遺伝子、新規3−ヒドロキシ酪酸脱水素酵素の製造法、ならびに、新規3−ヒドロキシ酪酸脱水素酵素を用いたケトン体の測定方法および測定用組成物
JP2019505193A (ja) * 2015-12-21 2019-02-28 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft アルカリゲネス・フェーカリス由来の変異型3−ヒドロキシ酪酸デヒドロゲナーゼ並びにそれに関する方法および使用
JP2019511245A (ja) * 2016-02-09 2019-04-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ロドバクター・スフェロイデス(Rhodobacter sphaeroides)由来の変異型3−ヒドロキシブチレート脱水素酵素及びそれを含む方法
WO2021149675A1 (ja) * 2020-01-24 2021-07-29 東洋紡株式会社 3-ヒドロキシ酪酸脱水素酵素及びその製造方法
WO2021210614A1 (ja) * 2020-04-17 2021-10-21 天野エンザイム株式会社 ケトン体測定用酵素剤、ケトン体測定用センサ及び試料中のケトン体を測定する方法

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ACTA CRYSTALLOGR. SECT. F, vol. 65, 2009, pages 331 - 335
ACTA MICROBIOL. POL., vol. 43, 1994, pages 33 - 45
BIOCHIM. BIOPHYS. ACTA, vol. 871, 1986, pages 302 - 309
CAN. J. MICROBIOL., vol. 19, 1973, pages 673 - 677
DATABASE UNIPROTKB 23 May 2018 (2018-05-23), XP093315880, Database accession no. A0A2P4RL44 *
J. BIOCHEM., vol. 89, 1981, pages 625 - 635
J. BIOSCI. BIOENG., vol. 101, 2006, pages 501 - 507
J. BIOSCI. BIOENG., vol. 97, 2004, pages 78 - 81
J. GEN. MICROBIOL., vol. 104, 1978, pages 123 - 126
J. MOL. BIOL., vol. 355, 2006, pages 722 - 733
SANGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 74, 1977, pages 5463
TAKANASHI, M. SAITO, T.: "Characterization of two 3-hydroxybutyrate dehydrogenases in poly(3-hydroxybutyrate)-degradable bacterium, Ralstonia pickettii T1", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, ELSEVIER, AMSTERDAM, NL, vol. 101, no. 6, 1 June 2006 (2006-06-01), NL , pages 501 - 507, XP005618850, ISSN: 1389-1723, DOI: 10.1263/jbb.101.501 *
TATIANA A. TATSUSOVATHOMAS L. MADDEN, FEMS MICROBIOL. LETT., vol. 174, 1999, pages 247 - 250

Also Published As

Publication number Publication date
JPWO2025105408A1 (cg-RX-API-DMAC7.html) 2025-05-22
CN122180765A (zh) 2026-06-09

Similar Documents

Publication Publication Date Title
CN101535476B (zh) 修饰型黄素腺嘌呤二核苷酸依赖性葡萄糖脱氢酶
JP6207167B2 (ja) 新規なグルコース脱水素酵素
EP2083074A1 (en) Modified flavine-adenine-dinucleotide-dependent glucose dehydrogenase
US9506042B2 (en) Glucose dehydrogenase
WO2013065623A1 (ja) 新規なグルコース脱水素酵素
JP6311270B2 (ja) 耐熱性に優れたフラビンアデニンジヌクレオチド依存性グルコースデヒドロゲナーゼ
JPWO2014045912A1 (ja) フラビンアデニンジヌクレオチド依存型グルコース脱水素酵素活性を有するタンパク質
WO2009087929A1 (ja) 新規なグルコースデヒドロゲナーゼ
JP6465156B2 (ja) 新規なグルコース脱水素酵素
JP6460513B2 (ja) フラビンアデニンジヌクレオチド依存型グルコース脱水素酵素活性を有するタンパク質
JP2004344145A (ja) 基質特異性または安定性に優れたピロロキノリンキノン(pqq)依存性グルコースデヒドロゲナーゼ改変体
JP7842407B2 (ja) 変異グルコースデヒドロゲナーゼ
JP5811521B2 (ja) フラビンアデニンジヌクレオチド依存性グルコースデヒドロゲナーゼの比活性を向上するための方法
JP2004313180A (ja) 基質特異性または安定性に優れたピロロキノリンキノン(pqq)依存性グルコースデヒドロゲナーゼ改変体
JP5216889B2 (ja) 新規l−アミノ酸オキシダーゼ、l−リジンの測定方法、キット及び酵素センサー
EP2305803B1 (en) Thermostable 1,5-anhydroglucitol dehydrogenase, and method for measurement of 1,5-anhydroglucitol by using the same
JP6342174B2 (ja) 新規なグルコースデヒドロゲナーゼ
JP4036667B2 (ja) 新規グルコース脱水素酵素及びそれをコードする遺伝子
WO2021210614A1 (ja) ケトン体測定用酵素剤、ケトン体測定用センサ及び試料中のケトン体を測定する方法
JP5799534B2 (ja) フラビンアデニンジヌクレオチド依存性グルコースデヒドロゲナーゼの安定性を向上するための方法
JP2009273381A (ja) 熱安定性が向上したフラビンアデニン依存性グルコースデヒドロゲナーゼ改変体
WO2025187833A1 (ja) 新規3-ヒドロキシ酪酸酸化酵素
JP2004313172A (ja) 基質特異性または安定性に優れたピロロキノリンキノン(pqq)依存性グルコースデヒドロゲナーゼ改変体
JP6390776B2 (ja) 耐熱性に優れたフラビンアデニンジヌクレオチド依存性グルコースデヒドロゲナーゼ
JP6619152B2 (ja) フラビンアデニンジヌクレオチド依存型グルコース脱水素酵素活性を有するキメラタンパク質

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24891444

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2025557884

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025557884

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2024891444

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024891444

Country of ref document: EP

Effective date: 20260615